Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial comparing administration of alvocidib given in timed-sequential-therapy with cytarabine and mitoxantrone with cytarabine and mitoxantrone alone in patients with acute myeloid leukaemia

Next Previous
Trial Profile

Phase III trial comparing administration of alvocidib given in timed-sequential-therapy with cytarabine and mitoxantrone with cytarabine and mitoxantrone alone in patients with acute myeloid leukaemia

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alvocidib (Primary) ; Cytarabine; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Pharma Oncology; Tolero Pharmaceuticals

Most Recent Events

  • 26 Jan 2017 This trial was being conducted by Tolero Pharmaceuticals. The Company has now been acquired by Sumitomo Dainippon Pharma, according to a Sumitomo Dainippon Pharma media release.
  • 09 Nov 2015 According to a Tolero Pharmaceuticals media release, after an end of phase II meeting with US FDA , 'rate of complete remission' was confirmed as the primary endpoint of this study.
  • 27 Feb 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top